FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665

Exhibit 10.4

FOIA CONFIDENTIAL TREATMENT REQUEST BY

▇▇▇▇▇▇▇▇▇ PHARMACEUTICALS, INC.

IRS EMPLOYER IDENTIFICATION NUMBER ▇▇-▇▇▇▇▇▇▇

***CONFIDENTIAL TREATMENT REQUESTED***

Note: Confidential treatment requested with respect to certain portions hereof denoted with “***”

Final

Date: May 15, 2015

Second Amended

and Restated Supply

and License

Agreement

Mayne Pharma Ventures Pty Ltd (Mayne Pharma)

▇▇▇▇▇▇▇▇▇ Pharmaceuticals, Inc. (HPPI)

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 1

Table of contents


Table of contents		2

Details		6

Agreed terms		8

1.	Defined terms & interpretation	8

1.1	Defined terms	8
1.2	Interpretation	11
1.3	Amendment and Restatement	12

2.	Term	12

2.1	Initial Term	12
2.2	Extension	12
2.3	Acknowledgment with respect to continuing obligations	12

3.	Licence	13

3.1	Licence to exploit the Product in the Territory	13
3.2	HPPI obligations	13
3.3	Supporting the exclusive licence	13
3.4	Sub licensing the MP Licensed Rights	14

4.	Development	14

4.1	Development Plan and Budget	14
4.2	JDC	14
4.3	Material development decisions	15
4.4	Mayne Pharma support	15

5.	Marketing Authorisation	16

5.1	Obtaining and maintaining Marketing Authorisations	16
5.2	Assistance by Mayne Pharma	17
5.3	Failure to obtain Marketing Authorisations	17

6.	Manufacture and supply of Product	17

6.1	Forecasts	17
6.2	Orders	17
6.3	Manufacture; Failure to Supply	17
6.4	Backup manufacturer	18

7.	Payments	18

7.1	HPPI Payments	18
7.2	Review of Prices	18
7.3	Mayne Pharma Payments	18
7.4	Payment terms	18
7.5	Reimbursement	19

8.	Delivery, risk and title	19

8.1	Delivery	19
8.2	Risk	19
8.3	Title	19

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 2


9.	Acceptance of Product	19

9.1	Certificate of Analysis	19
9.2	Defective Product	19
9.3	Sole remedy	20

10.	Complaints	20

10.1	Handling customer complaints	20
10.2	Notification of complaints	20
10.3	Adverse Drug Events	20
10.4	Supplementary agreements	20

11.	Recalls	20

11.1	Notice of recall	20
11.2	Directing that the Product be recalled	21
11.3	Administering a recall	21
11.4	Cost of the recall	21
11.5	Submission to independent analysis	21

12.	Performance obligations	21

12.1	Business Plan	21
12.2	Promotional Material	22
12.3	Efforts to maximise sales	22
12.4	Minimum Annual Volumes	22

13.	Compliance with laws and regulations	22

13.1	HPPI’s obligations	22
13.2	Mayne Pharma’s obligations	23
13.3	Anti-corruption	23

14.	Inspection	23

15.	Representations and warranties	24

15.1	Legal capacity and relationships	24
15.2	Mayne Pharma warranties	24
15.3	HPPI warranties	24

16.	Liability, indemnity and insurance	25

16.1	No exclusion or limitation	25
16.2	Exclusion and disclaimer of implied obligations	25
16.3	Limitation of liability regarding matters other than Non-Excludable Obligations	25
16.4	Indemnity	25
16.5	HPPI Insurance	25
16.6	Mayne Pharma Insurance	26
16.7	Maintain insurance	26
16.8	Evidence of insurance	26

17.	Confidentiality	26

17.1	Definition	26
17.2	Restrictions on disclosure and use	27
17.3	Exceptions	27

18.	Intellectual Property Rights	27

18.1	Intellectual Property Rights in the Product as at the Start Date	27

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 3


18.2	***	28
18.3	Reserved	28
18.4	***	28
18.5	Development of Intellectual Property Rights and Licence of HPPI Licensed Rights	28
18.6	Notification of infringement	28
18.7	Right to take action	28

19.	Branding	28

19.1	Directions regarding use of the Trade Mark	28
19.2	Samples of marketing materials	29
19.3	Use of the Trade Mark	29
19.4	Goodwill	29
19.5	No right for HPPI to register the Trade Mark	29

20.	Termination	29

20.1	Termination for breach by a party	29
20.2	Termination by Mayne Pharma for cause arising under a related agreement	29
20.3	Notification of insolvency events	30
20.4	Change of control and disposal of assets or business by HPPI	30
20.5	Impact of claims of infringement	30
20.6	Accrued rights and remedies	31
20.7	Sell down or repurchase	32
20.8	Return of Confidential Information	32

21.	Force majeure	32

21.1	Occurrence of Force Majeure Event	32
21.2	Termination	33

22.	Notices and other communications	33

22.1	Service of notices	33
22.2	Effective on receipt	33

23.	Dispute resolution	33

24.	GST	34

24.1	Interpretation	34
24.2	Consideration is GST exclusive	34
24.3	Gross up of consideration	34
24.4	The sale of the Product is intended to be a GST-free export of goods	34
24.5	Reimbursements (net down)	34
24.6	Tax invoices	35
24.7	Adjustments	35
24.8	Similar goods and services taxes or value added taxes	35

25.	Tax	35

25.1	Payments free of taxes; obligations to withhold; payments on account of taxes	35
25.2	Refunds	35

26.	Miscellaneous	36

26.1	Survival of Obligations	36
26.2	Approvals and consents	36
26.3	Announcements	36
26.4	Subcontracting	36
26.5	Assignment	36

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 4


26.6	Costs	36
26.7	Relationship	36
26.8	No modification	36
26.9	Non waiver	36
26.10	Entire agreement	37
26.11	Further Action	37
26.12	Severability	37
26.13	Counterparts	37
26.14	Governing law	37

Schedule 1 – Agreement details		38

Schedule 2 – Not used		39

Schedule 3 – Development Plan		40

Schedule 4 – Product and Product Specification		41

Schedule 5 – Economic details		42

Schedule 6 – Qualification of Backup Manufacturer		45

Schedule 7 – Licence of HPPI Licensed Rights		46

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 5

Details


Date		May 15, 2015

Parties

Name		Mayne Pharma Ventures Pty Ltd, an Australian company ACN 168 896 357
Short form name		Mayne Pharma
Notice details		Level ▇▇, ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇ Facsimile: ▇▇▇ ▇ ▇▇▇▇ ▇▇▇▇
		Attention: General Counsel

Name		▇▇▇▇▇▇▇▇▇ Pharmaceuticals, Inc., a company incorporated in Delaware, successor in interest by merger to Commonwealth Biotechnologies, Inc, a Virginia corporation
Short form name		HPPI
Notice details		▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ #▇▇▇, ▇▇▇▇▇, ▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇ Facsimile: ▇▇ ▇▇▇-▇▇▇-▇▇▇▇
		Attention: ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, President & CEO

Background

A	Mayne Pharma manufactures and has rights in respect of the Product.

B	HPPI develops and commercialises medicinal products.

C	On the terms and conditions set out in this Agreement:

(i)

Mayne Pharma agrees to supply HPPI with the Product and provide to HPPI a license to certain Intellectual Property Rights; and

(ii)

the parties agree to participate in the JDC.

D	Mayne Pharma International Pty Ltd, a company incorporated in Australia (ACN 007 870 984) (MPI) and HPPI entered into that certain Supply and License Agreement dated on or about September 3, 2013 (the “Original Agreement”).

E	MPI and HPPI entered into that certain Amendment No. 1 to the Original Agreement, dated on or about December 17, 2013 (“Amendment No. 1”).

F	MPI and HPPI entered into that certain Amendment No. 2 to the Original Agreement, dated on or about March 6, 2014 (“Amendment No. 2”).

G	MPI assigned, and ▇▇▇▇▇ Pharma assumed, the rights and obligations under the Original Agreement as amended by Amendment No. 1 and Amendment No. 2.

Mayne Pharma had the right to terminate the Original Agreement (as amended), if HPPI did not obtain equity funding of at least Five Million Dollars (USD5 million) or lesser amount as agreed to by the parties, on or before May 30, 2014. In consideration of Mayne Pharma not exercising such termination right, HPPI agreed to issue to Mayne Pharma in a private placement certain stock under the Mayne Pharma Purchase Agreement (as defined) and to enter into related agreements with Mayne Pharma, ▇▇▇▇▇▇▇▇▇, LLC (as defined) and others.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 6

Pursuant to clause 26.8 of the Original Agreement, Mayne Pharma and HPPI amended and replaced, in their entirety, their agreements as set forth in the Original Agreement, Amendment No. 1 and Amendment No. 2, with the agreements, terms, conditions, representations and warranties set forth in that certain Amended and Restated Supply Agreement, dated on or about June 24, 2014 (“First Amended and Restated Supply and License Agreement”).

J	MPI and HPPI entered into that certain Amendment No. 1 to the First Amended and Restated Supply Agreement, with effect from September 19, 2014 (“Amendment No. 1 to the First Amended and Restated Supply and License Agreement”).

Pursuant to clause 26.8 of the First Amended and Restated Supply and License Agreement, in connection with Mayne Pharma’s investment of Two Million Five Hundred Thousand Dollars (USD2.5 million) in HPPI under the 2015 SPA (as defined), Mayne Pharma and HPPI desire to amend and replace, in their entirety, their agreements as set forth in the First Amended and Restated Supply and License Agreement and Amendment No. 1 to the First Amended and Restated Supply and License Agreement, with the agreements, terms, conditions, representations and warranties set forth herein.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 7

Agreed terms

1.	Defined terms & interpretation

1.1

Defined terms

In this agreement:

Actual Launch Date means the date of the first commercial sale of the Product in any part of the Field, directly or indirectly, by HPPI.

Adverse Drug Event means any untoward medical occurrence in a patient or clinical investigation subject administered with the Product, including any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the Product, whether or not considered related to the Product.

Affected Obligations is defined in clause 21.1(a)(ii).

Affiliate means, with respect to a party, any person which, directly or indirectly, is controlled by, controls or is under common control with that party. In this definition, “control” means having the power to exercise or control the right to vote attached to 50% or more of the issued voting equity in that party, to appoint one half or more of the directors to the board or the managers of the party, or to determine substantially the conduct of the party’s business activities. Notwithstanding this definition, but solely for purposes of this Agreement and not applicable laws, rules and regulations generally, if Mayne Pharma controls HPPI:

(a)

Affiliates of HPPI will not include Mayne Pharma nor any person that would otherwise be an Affiliate of HPPI as a result of Mayne Pharma’s control of HPPI; and

(b)

Affiliates of Mayne Pharma will not include HPPI nor any person that would otherwise be an Affiliate of Mayne Pharma as a result of Mayne Pharma’s control of HPPI.

Agreement means this Second Amended and Restated Supply and License Agreement.

Alternate Product means any product ***.

API means active pharmaceutical ingredient.

Budget is defined in clause 4.1(b).

Business Day means:

(a)

for receiving a notice under clause 22, a day that is not a Saturday, Sunday, public holiday or bank holiday in the place where the notice is received; and

(b)

for performing an obligation or exercising a right by Mayne Pharma, a day that is not a Saturday, Sunday, bank holiday or public holiday in Melbourne, Australia;

(c)

for performing an obligation or exercising a right by HPPI, a day that is not a Saturday, Sunday, bank holiday or public holiday in New York, New York, USA; and

(d)

for all other purposes, a day that is not a Saturday, Sunday, bank holiday or public holiday in Melbourne, Australia.

Business Hours means the hours between 9am and 5pm on a Business Day.

Business Plan is the business plan provided by HPPI under clause 12.1 and updated from time to time in accordance with that clause.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 8

Certificate of Analysis means a document which is signed and dated by an authorised representative of Mayne Pharma containing analysis results and certifying that the Product conforms with the Product Specification.

Commercial Year means a year starting at the start of the first Quarter after the Target Launch Date.

Competing Product means ***.

Confidential Information is defined in clause 17.1.

CPI means the ‘Price Indexes of Materials Used in Manufacturing Industries, Australia’ issued by the Australian Bureau of Statistics using the index figure for chemicals.

Defective Product is defined in clause 9.2.

Delivery Date is defined in clause 6.2(c).

Developed Intellectual Property Rights is defined in clause 18.5.

Development Plan means the plan for the research, development and registration activities relating to the Product, as at the Start Date which shall be provided by HPPI to Mayne Pharma for approval as provided in clause 4.1, and as may be updated in accordance with clause 4.1(a) and 4.3(b).

Disclosing Party is defined in clause 17.1.

Equity Holders Agreement means the amended and restated equity holders agreement dated of even date herewith between Mayne Pharma, HPPI, ▇▇▇▇▇▇▇▇▇, LLC, ▇▇▇▇▇ ▇. ▇’▇▇▇▇▇▇▇, ▇▇., M.D. and ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇.

Field means treatment of human patients with cancer via oral administration. The initial three indications included within the Field shall be prostate, lung and skin cancer, which shall be developed in accordance with the Development Plan. It is agreed that HPPI has the exclusive right hereunder to develop the Product for additional indications in the Field; provided, however, that HPPI may not expand the Field to include any other types of cancer or any other medical indication unless agreed to in advance in writing by Mayne Pharma.

Force Majeure Event means, in relation to a party, anything outside the reasonable control of the party, including:

(a)

any act or omission of a third person (except for an act or omission of any Affiliate or contractor, or in relation to HPPI, any Sub Licensee);

(b)

fire, flood, earthquake, elements of nature or act of God; or

(c)

riot, civil disorder, rebellion or revolution.

Forecast is defined in clause 6.1(a).

Forecast Period is set out in Schedule 5.

Good Distribution Practice means the guidelines for the proper distribution of medicinal products for human use in the Territory, including in accordance with 21 CFR 210/211 and USP 1079, as each may be amended from time to time.

Good Manufacturing Practice means the guidelines for the proper manufacture of medicinal products for human use in the Territory, including in accordance with in accordance with 21 CFR 210/211, as may be amended from time to time.

▇▇▇▇▇▇▇▇▇, LLC means a ▇▇▇▇▇▇▇▇▇, LLC, a limited liability company organised in the State of Florida.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 9

HPPI Licensed Rights is defined in item 1 of Schedule 7.

HP Patents means each of US patent application 61/813,122 (prostate-specific antigen as biomarker for hedgehog pathway inhibitor treatment and prognostic monitoring of prostate cancer) and US patent application 61/831,823 (Treatment and Prognostic Monitoring of Cancer Using Hedgehog Pathway Inhibitors) in the name of ▇▇▇▇▇▇▇▇▇, LLC and any resulting issued patents whether or not in the Territory, and all continuations-in-part, continuations or divisions of any such patent or patents, or substitutes of it, and any reissues, extensions, or renewals of it, whether or not in the Territory.

Initial Term is set out in Schedule 1.

Intellectual Property Rights or IPR means all intellectual property rights subsisting anywhere in the world, including:

(a)

inventions, know how, patents, copyrights, designs, trade and service marks, logos and any right to have information kept confidential; and

(b)

any application or right to apply for registration of any of the rights referred to in paragraph (a),

whether or not such rights are registered or capable of being registered.

JDC is defined in clause 4.2.

Marketing Authorisation means a registration, approval or licence from a Relevant Regulatory Authority in the Territory for the importation, storage, promotion, sale or distribution of the Product in the Field.

Mayne Pharma Purchase Agreement is defined in the Equity Holders Agreement.

MP Licensed Rights means all Intellectual Property Rights in the Product existing as at the Start Date and owned by Mayne Pharma or its Affiliates:

(a)

comprising, in respect of patent rights, *** in the name of Mayne Pharma, together with and any resulting issued patents in the Territory, and all continuations-in-part, continuations or divisions of any such patent or patents, or substitutes of it, and any reissues, extensions, or renewals of it, in the Territory; and

(b)

excluding rights in respect of trade and service marks and logos.

Minimum Annual Volume for the Product is as agreed by the parties in accordance with item 1.2 of Schedule 5.

Minimum Order Quantity means the batch size for the Product as set out in Schedule 5.

***.

Off Label Sales is defined in clause 7.3(a).

Order is defined in clause 6.2(a).

Personnel, of a party, means its employees, officers, directors, agents, consultants and contractors (to avoid doubt, such contractors not including the other party).

Precluded Extent is defined in clause 21.1.

Precluded Party is defined in clause 21.1.

Price is set out in Schedule 5.

Product means the product set out in Schedule 4, and any other product agreed by the parties in writing for the purposes of this Agreement from time to time (at which time the parties must also agree in

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 10

writing related amendments to Schedule 4 and Schedule 5), it being acknowledged and agreed that the term “Product” may include products covering different medical indications developed under the Development Plan, provided the same are included within the scope of the Field.

Product Specification means the specification with respect to the manufacture, packaging, quality and characteristics (including the raw materials and product specification) and testing of the Product, as set out in Schedule 4.

Quality Agreement means the technical agreement between the parties detailing the specification and technical terms for the manufacture of the Product as set out in the Marketing Authorisation.

Quarter means a 3 month period starting 1 January, 1 April, 1 July or 1 October.

reasonable commercial efforts means ***.

Recipient is defined in clause 17.2.

Relevant Regulatory Authority, in relation to a country or region in or comprising the Territory, means any governmental authority (whether federal, state or local) regulating the manufacture, importation, storage, promotion, sale, distribution or use of therapeutic substances, and in the case of Australia and the USA includes the Therapeutic Goods Administration (TGA) and the Food and Drug Administration (FDA) respectively, or any successor body.

Safety Data Exchange Agreement (SDEA) means the agreement between the parties setting out the rules and procedures for exchanging information concerning certain safety and pharmacovigilance issues.

Sales Forecast is set out in item 1.2 of Schedule 5.

Start Date is set out in Schedule 1.

Sub Licensee is defined in clause 3.4.

Tax means any tax (including any GST or VAT), withholding tax, duties, levies, charges, fees and other imposts of any kind (including any fine, interest, penalty and expenses in connection with those items) levied, assessed, charged or collected in connection with this Agreement or the performance of services under this Agreement, but does not include any income or capital gains tax.

Target Launch Date is 30 June 2017, as that date may be extended by agreement of the parties in writing.

Term means the Initial Term and any extensions under clause 2.2.

Territory is set out in Schedule 1.

Trade Mark means US trade mark (number 77793077) “SUBA” for goods and services in class 5 (pharmaceutical and veterinary preparations having enhanced bioavailability excluding pharmaceutical products for the treatment of opioid addiction) and any other trademarks (whether registered or unregistered) notified in writing by Mayne Pharma to HPPI for the purposes of this Agreement from time to time.

2015 SPA is defined in the Equity Holders Agreement.

1.2

Interpretation

In this Agreement, except where the context otherwise requires:

(a)

the singular includes the plural and vice versa, and a gender includes other genders;

(b)

another grammatical form of a defined word or expression has a corresponding meaning;

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 11

(c)

a reference to a clause, paragraph, schedule or annexure is to a clause or paragraph of, or schedule or annexure to, this Agreement, and a reference to this Agreement includes any schedule or annexure;

(d)

a reference to a document or instrument includes the document or instrument as novated, altered, supplemented or replaced from time to time;

(e)

a reference to AUD is to Australian dollars, to USD is to United States dollars, to GBP is to British pounds and to EUR is to euros;

(f)

a reference to time is to Melbourne, Australia time;

(g)

a reference to a party is to a party to this Agreement, and includes the party’s executors, administrators, successors and permitted assigns and substitutes;

(h)

a reference to a person includes a natural person, partnership, corporation, limited liability company, trust, association, governmental or local authority or agency or other entity;

(i)

a reference to a statute, ordinance, code or other law includes regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of them;

(j)

the meaning of general words is not limited by specific examples introduced by including, for example or similar expressions;

(k)

a rule of construction does not apply to the disadvantage of a party because the party was responsible for the preparation of this Agreement or any part of it;

(l)

if a day on or by which an obligation must be performed or an event must occur is not a Business Day, the obligation must be performed or the event must occur on or by the next Business Day;

(m)

headings are for ease of reference only and do not affect interpretation; and

(n)

clauses 1 and 26 prevail over a Schedule to the extent of any inconsistency.

1.3

Amendment and Restatement

Mayne Pharma and HPPI hereby agree by their mutual execution hereof that this Agreement amends, restates and supersedes, in their entirety, effective as of May 15, 2015, each and all their agreements as set forth in the First Amended and Restated Supply and License Agreement and Amendment No. 1 to the First Amended and Restated Supply and License Agreement.

Term

2.1

Initial Term

This Agreement starts effective as of the Start Date and continues for the Initial Term unless terminated in accordance with its terms and conditions.

2.2

Extension

This Agreement automatically continues after the Initial Term for additional periods of ***, unless a party gives notice of its wish not to extend this Agreement at least *** before the end of the Initial Term or any extended term under this clause 2.2 or this Agreement is terminated in accordance with its terms and conditions.

2.3

Acknowledgment with respect to continuing obligations

HPPI acknowledges that Mayne Pharma has no ongoing obligations with respect to the continuing grant of the IP licence other than under clauses 3.3, 4.1(a) and 4.1(g). This does not limit Mayne Pharma’s obligations to the supply of Product and its related obligations in the remainder of this Agreement, including under clauses 5.2, 6 to 11 and clause 13.2.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 12

LICENCE

Licence

3.1

Licence to exploit the Product in the Territory

Mayne Pharma grants to HPPI an exclusive licence to exploit the Product in the Field in the Territory, including:

(a)

to conduct the activities in the Territory under the Development Plan; and

(b)

to import, promote, market, sell and distribute the Product in the Territory,

which licence:

(c)

comprises the right to copy and exploit the MP Licensed Rights and to use the Trade Mark, to the extent reasonably necessary or desirable to exploit the Product in the Field in the Territory;

(d)

may only be assigned or sub licensed in accordance with this Agreement or otherwise with the prior written consent of Mayne Pharma; and

(e)

excludes the right to manufacture, except by a Backup Manufacturer in accordance with Schedule 6.

3.2

HPPI obligations

HPPI must:

(a)

obtain from Mayne Pharma all its requirements for the Product, including for clinical trials, importation, promotion, marketing, sale or distribution in the Territory;

(b)

not directly itself, or indirectly through any third party:

(i)

research, develop, manufacture, import, promote, market, sell, distribute or otherwise have any commercial interest or involvement in any Competing Product in the Territory during the Term and *** after the end of the Term; or

(ii)

sell or distribute the Product to any other party which it knows, or has reasonable grounds for suspecting, will sell or distribute the Product outside the Territory or outside the Field;

(iii)

import, promote, market, sell or distribute the Product outside the Territory or outside the Field; and

(c)

refer to Mayne Pharma all enquiries, sales leads, prospects and other information HPPI may receive concerning sales and prospective sales of the Product outside the Territory or the Field.

3.3

Supporting the exclusive licence

Mayne Pharma must not, directly itself or indirectly through any third party, import, promote, market, distribute or sell the Product or any Competing Product in the Territory in the Field during the Term, other than as a result of any off label use of an Alternate Product which the parties acknowledge is outside the reasonable control of Mayne Pharma (but subject to the provisions of clause 7.3 hereof).

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 13

3.4

Sub licensing the MP Licensed Rights

HPPI may only grant a sub licence of the MP Licensed Rights and the Trade Mark to a third party (including any Affiliate or approved contractor) (Sub Licensee) with the prior written consent of Mayne Pharma under a written agreement that:

(a)

includes obligations on that third party that relate to use and disclosure of Intellectual Property Rights and Confidential Information at least equivalent to those imposed on the HPPI under this Agreement, without any right of further disclosure or sub license;

(b)

ends at the same time as this Agreement ends (whether by expiry or termination); and

(c)

includes an assignment to HPPI of all Intellectual Property Rights that relate to the Product,

and HPPI remains responsible for ensuring its Sub Licensees comply with such written agreement.

4.	Development

4.1

Development Plan and Budget

(a)

Within *** of the execution of this Agreement, HPPI will propose to Mayne Pharma, and Mayne Pharma shall approve, an updated Development Plan as recommended by the JDC. Such Development Plan, as finally approved by both parties, shall be included as an updated Schedule 3 hereto and shall be deemed an integrated part of this Agreement.

(b)

Within *** of the execution of this Agreement, HPPI will propose to Mayne Pharma a budget for HPPI to conduct its activities (***) *** (once approved, the Budget). ***.

(c)

The Budget shall include a detailed listing of (amongst other customary matters for budgets for the clinical development of a pharmaceutical product), including third party service provider costs to be borne by HPPI.

(d)

HPPI and Mayne Pharma will conduct the activities set out in, and in accordance with, the Development Plan and further in accordance with the Budget.

(e)

Up until the Target Launch Date, the parties must review the Development Plan and the Budget through the JDC ***.

(f)

***.

(g)

Mayne Pharma agrees to provide, as part of its services pursuant to clause 4.4 and at its expense, the relevant CMC section of the Product dossier to support pre-IND activities set out in the Development Plan as of the Start Date.

4.2

JDC

(a)

Within *** from the Start Date, the parties will form a joint development committee (JDC):

(i)

to make recommendations to HPPI on research, development and registration activities relating to the exploitation of the Product in the Field in the Territory, including medico regulatory strategy;

(ii)

to review progress against the current Development Plan and Budget and recommend amendments to HPPI;

(iii)

to consider and make recommendations to HPPI for appropriate intellectual property protection for the outcomes of any research and development;

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 14

(iv)

to direct the conduct of entire clinical program for the Product,

which JDC will continue until the Target Launch Date. The parties acknowledge and agree that the JDC is solely advisory in nature, shall have no power or authority to legally bind HPPI or Mayne Pharma, and at all times shall remain subject to the authority of the board of directors of HPPI. ***.

(b)

Each of the parties will appoint two representatives to the JDC. In addition, from time to time the parties may, by agreement in writing, invite additional representatives from either party, or industry experts or consultants, to participate in certain meetings on specific issues as needed, at HPPI’s cost and expense. ***.

(c)

Each of the parties may change its representatives at any time during the term of this Agreement by notice to the other party, except that ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇ will be a representative of HPPI from the Start Date unless or until it is no longer possible for reasons outside HPPI’s reasonable control.

(d)

Each member of the JDC (including the chairperson) shall be entitled to one (1) vote on all matters which must be presented under this Agreement (or which are otherwise presented) to the JDC for approval, with the chairperson to have a casting vote that resolves any deadlock. The JDC shall fully abide by such vote or action in the conduct of its affairs, subject always to clause 4.2(a) and the continuing authority of the board of directors of HPPI.

(e)

The JDC may hold meetings in person, by teleconference or by video conference:

(i)

on a regular basis until the Target Launch Date, but not less than one per month;

(ii)

as otherwise reasonably requested by the parties.

The JDC may also take action by written consent of the JDC members, and a majority of the JDC members may act by written consent on any matter which must be presented under this Agreement (or which are otherwise presented) to the JDC for approval.

(f)

The site, date and proposed agenda of any meeting of the JDC must be determined by agreement of the members of the JDC.

4.3

Material development decisions

HPPI agrees that any material decisions regarding the following are subject to the prior written consent of Mayne Pharma, such consent not to be unreasonably withheld, conditioned or delayed:

(a)

the research, development and registration of the Product by HPPI;

(b)

any material amendments to the Development Plan or the Budget; and

(c)

the seeking of appropriate intellectual property protection for the outcomes of any research and development (including any decision to disclose Confidential Information of HPPI relating to the Product, and any filing, prosecution or maintenance of patent rights), all of which, for the avoidance of doubt, shall be considered Developed Intellectual Property Rights subject to clause 18.5 and Schedule 7.

4.4

Mayne Pharma support

(a)

From the date of this Agreement until ***, Mayne Pharma will provide to HPPI, from time to time, the following services in connection with the exploitation of the Product in the Territory in the Field and the conduct of the Development Plan, comprising:

(i)

coordinating the JDC meetings;

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 15

(ii)

directing the conduct of the entire clinical program for the Product, subject to the oversight and approval by the JDC and, as applicable hereunder or for other matters binding on HPPI, the HPPI board of directors;

(iii)

medico regulatory strategy, including directing a third party (at HPPI’s expense, subject to clause 4.4(b)) to prepare the regulatory documents to progress and file any Marketing Authorisation, including any application for, maintenance of or variation of, any Marketing Authorisation, for the Product;

(iv)

intellectual property strategy; and

(v)

other administrative services as agreed with HPPI,

but excluding, without limitation, the provision of legal, tax, accounting or other professional advice.

(b)

Mayne Pharma shall obtain HPPI’s advance approval (which may be undertaken by email by HPPI’s President, Chief Executive Officer or Chief Financial Officer) prior to providing such services on a case by case basis (including, for the avoidance of doubt, services which require, or would with the passage of time require, cash outlays by or material obligations of HPPI). Mayne Pharma shall use reasonable commercial efforts in performing such services, and shall perform such services in accordance with all applicable laws, rules and regulations.

(c)

Mayne Pharma shall provide all such services in accordance with the Development Plan and within the spending guidelines set out in the Budget. The cost of Mayne Pharma’s internal personnel and other internal costs and expenses incurred by Mayne Pharma in the provision of such services shall be borne by Mayne Pharma.

(d)

HPPI shall, at its expense, reimburse Mayne Pharma for any third party costs incurred by Mayne Pharma in connection with the provision of such services, subject to Mayne Pharma’s compliance with clauses 4.4(b), 4.4(c) and subject to clause 7.5. Where possible, third party costs to be incurred in connection with the provision of such services will be invoiced directly to HPPI.

(e)

For purposes of HPPI’s and Mayne Pharma’s accounting and reporting, each party shall reasonably cooperate with the other should the other party request any accounting or financial information relating to Mayne Pharma’s services under this clause 4.4.

5.	Marketing Authorisation

5.1

Obtaining and maintaining Marketing Authorisations

HPPI must:

(a)

actively seek, in coordination with the JDC and Mayne Pharma and at its own cost and expense (other than for services provided by Mayne Pharma under clause 4.4), and use reasonable commercial efforts to obtain all Marketing Authorisations in its own name;

(b)

pay fees or charges in respect of the application for all Marketing Authorisations, maintenance of all Marketing Authorisations and the making of any variation to all Marketing Authorisations; and

(c)

comply with the requirements of any Relevant Regulatory Authority within the Territory, including in connection with any Marketing Authorisation and all reporting obligations.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 16

5.2

Assistance by Mayne Pharma

Mayne Pharma will, at HPPI’s cost and expense other than for services provided under clause 4.4:

(a)

assist HPPI in connection with any Marketing Authorisation, including any application for, maintenance of or variation of, any Marketing Authorisation; and

(b)

provide any documents required by HPPI in connection with any Marketing Authorisation.

5.3

Failure to obtain Marketing Authorisations

If, notwithstanding HPPI’s compliance with clause 5.1, a Marketing Authorisation has not been obtained by HPPI, any Affiliate or Sub Licensee at least *** before the Target Launch Date, then following consultation with the other party for up to ***, either party, acting reasonably, may terminate this agreement with immediate effect with notice to the other party.

OBLIGATIONS RELATING TO SUPPLY OF PRODUCT

6.	Manufacture and supply of Product

6.1

Forecasts

(a)

On the ***, HPPI must provide Mayne Pharma with a forecast of its monthly requirements for the Product for the following Forecast Period (Forecast).

(b)

The first Forecast will include ***. For each subsequent Forecast:

***

6.2

Orders

(a)

HPPI must provide Mayne Pharma with a purchase order setting out the quantities of the Product, desired delivery date and delivery instructions (Order), ***.

(b)

Each Order must be for at least the Minimum Order Quantity, and any amount above the Minimum Order Quantity for whole multiples of any incremental order quantity specified in item 1 of Schedule 5, unless the parties agree otherwise in writing before an Order is placed.

(c)

Within *** of receipt by Mayne Pharma of an Order, Mayne Pharma must confirm its acceptance in writing and notify HPPI of the expected date of delivery (Delivery Date) of the Product. Without limitation, Mayne Pharma may refuse to confirm any quantity of Orders in a Quarter to the extent they exceed *** of the most recent Forecast provided by HPPI for that Quarter.

(d)

Mayne Pharma agrees to use reasonable commercial efforts:

(i)

to provide a Delivery Date *** after the delivery date specified in the Order; and

(ii)

to supply the Order by the Delivery Date.

(e)

No Order amends this Agreement unless HPPI expressly states in the Order that it seeks to amend this Agreement, and ▇▇▇▇▇ Pharma agrees in writing to the Order.

6.3

Manufacture; Failure to Supply

(a)

Mayne Pharma will manufacture the Product in accordance with all confirmed Orders received from HPPI.

(b)

In the situation where Mayne Pharma is not able to supply Product, or Mayne Pharma anticipates that it will be unable to supply Product to HPPI in satisfaction of HPPI’s Orders or forecasted Orders, Mayne Pharma shall use reasonable commercial efforts:

(i)

to inform HPPI in a timely manner about such situation and the details causing such situation; and

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 17

(ii)

to provide HPPI with a reasonable estimate of the length and extent of production interruption or other issue affecting Mayne Pharma’s satisfaction of HPPI’s Product demand.

6.4

Backup manufacturer

HPPI is entitled to qualify an alternate manufacturer of the Product in accordance with Schedule 6.

Payments

7.1

HPPI Payments

In consideration for Mayne Pharma manufacturing and delivering the Products in accordance with this Agreement, HPPI must make the payments set out in, and comply with, Schedule 5.

7.2

Review of Prices

(a)

Mayne Pharma has the right to review and vary any Floor Price set out in Schedule 5 by giving *** notice to HPPI, to reflect any changes in:

***

(b)

Mayne Pharma will consult with HPPI during the *** period of notice of a variation under clause 7.2.

7.3

Mayne Pharma Payments

(a)

The parties acknowledge that notwithstanding clause 3.3, there is a risk that Mayne Pharma may, directly itself or indirectly through any third party, sell an Alternate Product in the Territory in the Field as a result of off label use (Off Label Sales).

(b)

If HPPI becomes aware of any Off Label Sales in any Quarter ***, it must notify Mayne Pharma promptly, and in any event, no later than ***, and provide Mayne Pharma with its evidence of such Off Label Sales.

(c)

Prior to a Marketing Authorisation being obtained by HPPI, any Affiliate or Sub Licensee, within *** after receipt of a notice from HPPI under clause 7.3(b), Mayne Pharma must pay to HPPI a cash royalty of *** on gross sales up to USD*** and *** on gross sales over USD*** for the relevant Quarter for the Alternate Product sold through Off Label Sales ***.

(d)

After a Marketing Authorisation is obtained by HPPI, any Affiliate or Sub Licensee, if Off Label Sales of any Alternate Product exceed ***, then the parties agree to enter into a good faith negotiation to enter into an arrangement under which they will share profits from Off Label Sales of any Alternate Product ***.

7.4

Payment terms

Each party must make payments due under this Agreement:

(a)

in the currency specified in Schedule 5 and where necessary, converted:

(i)

in respect of any payment covering a Quarter, at the average daily exchange rate for the applicable Quarter as published by the financial institution specified in Schedule 5; and

(ii)

otherwise, at the daily exchange rate quoted by the financial institution specified in Schedule 5 on the date of payment;

(b)

to the bank account of the other party listed on the relevant invoice, with the party making payment to bear the costs of any such remittance; and

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 18

(c)

in the case of payments due to Mayne Pharma, to Mayne Pharma or its nominee as specified on the relevant invoice.

7.5

Reimbursement

Where a party agrees to reimburse to the other party any costs or expenses, then it will reimburse these amounts within *** from receipt of the other party’s invoice for, and reasonable evidence of, such costs or expenses.

8.	Delivery, risk and title

8.1

Delivery

Mayne Pharma must deliver the Product to HPPI in accordance with the delivery terms set out in item 3 of Schedule 5. Any Product that HPPI is paying for must have the minimum shelf life specified in item 4 of Schedule 5.

8.2

Risk

All risk of loss or of damage to the Product will pass to HPPI upon delivery of the Product in accordance with the delivery terms set out in item 3 of Schedule 5.

8.3

Title

Title to the Product will pass to HPPI upon payment in full of the Price payable for that Product or if no amount is payable, then on delivery.

9.	Acceptance of Product

9.1

Certificate of Analysis

Each delivery of the Product will be accompanied by a Certificate of Analysis from Mayne Pharma in respect of the Product so delivered.

9.2

Defective Product

(a)

HPPI must notify Mayne Pharma within *** of delivery of the Product if HPPI reasonably believes any of the Product does not conform to the Product Specification (Defective Product).

(b)

If HPPI gives notice under clause 9.2(a), the parties agree to consult with each other to resolve the issue (during which time Mayne Pharma may conduct its own retention sample testing). If the discrepancy is not resolved within a further *** from the receipt of the notice, the parties agree to appoint (at HPPI’s expense) an independent analyst, acceptable to both parties, that will carry out tests on representative samples taken from such shipment, and the results of such tests will be binding on the parties.

(c)

If HPPI does not notify Mayne Pharma in accordance with clause 9.2(a), then HPPI will be deemed to have accepted the Product at the end of the *** period after delivery of the Product.

(d)

If the independent analyst determines that the Defective Product does not conform to the Product Specification and as long as the Product has been transported, handled and stored in accordance with the Marketing Authorisation and all reasonable directions of Mayne Pharma once the Product has left Mayne Pharma’s facility, then:

(i)

Mayne Pharma must, at its expense, replace any such Defective Product and reimburse HPPI for the costs of the independent analyst; and

(ii)

all quantities of Defective Product must, at Mayne Pharma’s election and expense be either:

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 19

(A)

returned to Mayne Pharma at an address notified by Mayne Pharma, and packed and shipped according to instructions provided by Mayne Pharma; or

(B)

destroyed by HPPI under Mayne Pharma’s direction.

(e)

If:

(i)

the independent analyst determines that the Defective Product does conform to the Product Specification; or

(ii)

the Product has not been transported, handled and stored in accordance with the Marketing Authorisation and all reasonable directions of Mayne Pharma once the Product has been delivered to HPPI in accordance with this Agreement,

then HPPI is deemed to have accepted the Product and will reimburse Mayne Pharma for any costs and expenses incurred by Mayne Pharma in attempting to resolve the issue, including the costs of any retention sample testing conducted by Mayne Pharma.

9.3

Sole remedy

Despite any other provision in this Agreement, HPPI’s sole remedy in respect of Product which fails to conform to the Product Specification is, and Mayne Pharma’s liability to HPPI under this Agreement will be, limited as set out in clauses 9.2 and 16.3.

10.	Complaints

10.1

Handling customer complaints

HPPI must handle all customer complaints relating to any Product in the Territory and any related activities associated with reporting or management of customer complaints.

10.2

Notification of complaints

If HPPI becomes aware of any material complaint in connection with the Product, it must promptly notify Mayne Pharma of the complaint and provide details.

10.3

Adverse Drug Events

HPPI must advise Mayne Pharma as soon as reasonably practicable after becoming aware of any Adverse Drug Event.

10.4

Supplementary agreements

(a)

For Product supplied for clinical trial use, the parties will enter into an agreement outlining the party’s responsibilities with respect to the use of the Product for that purpose.

(b)

The parties must execute a Safety Data Exchange Agreement and Quality Agreement at least *** before the Target Launch Date.

(c)

This Agreement prevails to the extent of any inconsistency between it and the Safety Data Exchange Agreement or the Quality Agreement. To avoid doubt, clause 10.1 to 10.3 do not limit any obligations under the Safety Data Exchange Agreement and Quality Agreement.

11.

Recalls

11.1

Notice of recall

If a party determines any quantity of the Product should be recalled for any reason, or a party is notified of a recall, that party must give the other party notice within the time frames set out in the

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 20

Safety Data Exchange Agreement of its request to recall that quantity and specify its reasons. If a party determines that to avoid an immediate perceived threat to health, time does not permit the provision of notice, such notice may be made by telephone or e-mail transmission to the other party’s medical affairs liaison and quality contact person to be confirmed in writing after such notice.

11.2

Directing that the Product be recalled

If, within *** of the receipt of notice under clause 11.1, the parties are unable to agree on the need to undertake a recall (including after HPPI discusses the issue with the Relevant Regulatory Authority), then either party may direct that the Product be recalled, with or without the agreement of the other party, if it reasonably determines that such recall is necessary to protect the public health or is necessary to ensure compliance with applicable laws, rules and regulations.

11.3

Administering a recall

HPPI must administer any recall of the Product in the Territory.

11.4

Cost of the recall

If the cause of the recall is because the Product does not conform to the Product Specification, and it is as a result of a breach of warranty or negligence by Mayne Pharma, then Mayne Pharma must, at its expense, reimburse to HPPI for all its reasonable costs and expenses of any recall and the costs of any independent analyst engaged under clause 11.5. Otherwise, all costs and expenses in respect of the recall and the independent analyst are payable by HPPI.

11.5

Submission to independent analysis

If the parties cannot agree on whether the Product conformed to the Product Specification, then the parties agree to submit a sample of the Product to an independent analyst, acceptable to both parties, for a report. Absent manifest error, the finding of the independent analyst is binding on the parties

PERFORMANCE OBLIGATIONS

12.	Performance obligations

12.1

Business Plan

(a)

At least *** before the Target Launch Date, HPPI must provide a business plan to Mayne Pharma in connection with the distribution of Product in the Territory outlining the sales and marketing of the Product in the Territory from the Target Launch Date until the end of *** later, which plan must include market situational analysis, market segmentation, targeting and position, marketing strategies and selling strategies.

(b)

After the Target Launch Date, the parties must meet *** to review HPPI’s Business Plan outlining the sales and marketing of the Product in the Territory for the following ***. In developing the Business Plan, HPPI will use *** or similar locally sourced data, provided such data are available. The parties will discuss such Business Plan in good faith and HPPI may amend such Business Plan following the discussions.

(c)

If HPPI fails to update the Business Plan in accordance with clause 12.1(b), the then current Business Plan will continue until updated in accordance with that clause.

(d)

HPPI will use reasonable commercial efforts to achieve the objectives in the Business Plan.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 21

12.2

Promotional Material

(a)

HPPI is responsible for all sales, distribution, public relations, medical education and similar expenses related to HPPI’s promotion and marketing of the Product in the Territory.

(b)

Mayne Pharma will, at its own expense, provide to HPPI information relating to the Product and promotional information available to Mayne Pharma which HPPI reasonably requires for the promotion and marketing of the Product in the Territory but only to the extent that Mayne Pharma has the right to provide such information.

(c)

HPPI will provide to Mayne Pharma at Mayne Pharma’s expense information relevant to Mayne Pharma’s business outside the Territory.

(d)

HPPI must make available to Mayne Pharma samples of all materials (including all advertisements, promotions and other marketing material) used by it in respect of the Product, and grants to Mayne Pharma a non-exclusive, perpetual, irrevocable, royalty free licence to use those materials in connection with the importation, promotion, marketing, sale or distribution of the Product outside the Territory, which licence is capable of sub license to any Affiliate or licensee of Mayne Pharma.

12.3

Efforts to maximise sales

From the Target Launch Date:

(a)

until the Minimum Annual Volumes for the Product have been agreed by the parties as provided for in Schedule 5 of this Agreement, HPPI must use best efforts to maximise the sale of the Product in the Territory; and

(b)

after Minimum Annual Volumes have been established as provided for in Schedule 5 of this Agreement, HPPI must use reasonable commercial efforts to maximise the sale of the Product in the Territory.

12.4

Minimum Annual Volumes

(a)

HPPI will purchase in each Commercial Year at least the Minimum Annual Volumes as agreed to by the parties in accordance with Schedule 5 hereof.

(b)

If, in any Commercial Year, HPPI purchases less than the Minimum Annual Volumes, HPPI may elect to pay to Mayne Pharma the difference between the aggregate Prices paid for the volume of Product actually purchased for that Commercial Year and the value of the Minimum Annual Volumes for that Commercial Year, within *** of the end of that Commercial Year.

(c)

If, in any Commercial Year, HPPI purchases less than the Minimum Annual Volumes and has not elected to pay to Mayne Pharma the amount under clause 12.4(b) within *** of the end of the Commercial Year, then Mayne Pharma may, with immediate effect by notice to HPPI, terminate this Agreement.

13.	Compliance with laws and regulations

13.1

HPPI’s obligations

HPPI must:

(a)

promptly obtain and maintain as and when required all necessary registrations, permits, approvals and licences in respect of HPPI’s activities under this Agreement;

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 22

(b)

advise Mayne Pharma of any matters necessary or relevant to be known by Mayne Pharma to ensure that it manufactures the Product in compliance with all applicable laws, rules and regulations;

(c)

conduct the activities under the Development Plan, and import, promote, market, sell and distribute the Product in accordance with all laws, rules and regulations, Good Distribution Practice and any Marketing Authorisation; and

(d)

transport, handle and store the Product in accordance with any Marketing Authorisation and all reasonable directions specified by Mayne Pharma not inconsistent with any Marketing Authorisation.

13.2

Mayne Pharma’s obligations

Mayne Pharma must:

(a)

obtain and maintain, as and when required, all necessary registrations, permits, approvals and licences in respect of Mayne Pharma’s activities under this Agreement, including in respect of the manufacture of the Product in Australia;

(b)

manufacture the Product in accordance with all laws in Australia (or such other jurisdiction in which the Product is manufactured) and the Marketing Authorisation;

(c)

manufacture the Product in accordance with Good Manufacturing Practices;

(d)

ensure that Mayne Pharma’s premises comply with standards stipulated by relevant State or Commonwealth authorities of Australia; and

(e)

transport, handle and store the Product in accordance with all laws and Marketing Authorisations.

13.3

Anti-corruption

(a)

Without limitation, each party represents that it is now in compliance with, and will at all times remain in compliance with, all applicable laws and regulations relating to anti-corruption in Australia and in the Territory (including the US Foreign Corrupt Practice Act), as well as the UK Bribery Act 2010 and related regulations, and any other applicable anti-corruption laws prohibiting bribery or other forms of corruption, including money laundering, within the public and private sectors.

(b)

Except as disclosed in writing, each party warrants that:

(i)

it does not have any interest which directly or indirectly conflicts with its proper and ethical performance of this Agreement; and

(ii)

it will maintain arms-length relations with all third parties (including government officials) with which it deals for, or on behalf of, the other party.

14.	Inspection

Each party must procure that the other party or its authorised representative may, at the other party’s expense and on reasonable notice, visit and inspect the facilities of the first party, its Affiliates, sub licensees or its contractors used in respect of the Product (not more than once per year), to ensure compliance with this Agreement.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 23

LIABILITY

15.	Representations and warranties

15.1

Legal capacity and relationships

Each party represents and warrants that:

(a)

it is a corporation organised and validly existing under the laws of its jurisdiction of incorporation and has the legal capacity and authority to enter this Agreement and perform its obligations under this Agreement; and

(b)

this Agreement is a valid and binding obligation of that party enforceable in accordance with its terms, and it will not become a party to any agreement in conflict with this Agreement.

15.2

Mayne Pharma warranties

(a)

Mayne Pharma represents and warrants that the Product supplied to HPPI under this Agreement:

(i)

will conform in all material respects to the Product Specification; and

(ii)

will be manufactured in conformity with Good Manufacturing Practice, in accordance with all Marketing Authorisations and in accordance with all laws in Australia.

(b)

Mayne Pharma represents and warrants that it is the lawful and exclusive owner of the entire right, title and interest in and to all MP Licensed Rights.

(c)

To the extent permitted by law, Mayne Pharma makes no other representations or warranties, express or implied, with respect to the Product or this Agreement. In particular:

(i)

Mayne Pharma does not warrant that the importation or sale of the Product in the Territory will not infringe the Intellectual Property Rights of any third party; and

(ii)

Except as expressly provided for in clause 4.4, Mayne Pharma provides no warranties in respect of the provision of the services referred to in clause 4.4.

15.3

HPPI warranties

HPPI represents and warrants that:

(a)

as at the Start Date:

(i)

HPPI is successor by merger to Commonwealth Biotechnologies, Inc, a Virginia corporation;

(ii)

the Amended Plan of Reorganization of CBI (the Plan), dated January 4, 2013, and filed in In re: Commonwealth Biotechnologies, Inc., Case No. 11-30381-KRH, U.S. Bankruptcy Court, E.D. Virginia (the Case), has been confirmed pursuant to a final and non-appealable order of the bankruptcy court;

(iii)

HPPI has delivered a true, correct and complete copy of the Plan with all amendments to Mayne Pharma;

(iv)

the Effective Date, as defined in the Plan, has occurred and is August 12, 2013 and HPPI has taken all actions reasonable and necessary to formally close the Case;

(v)

there are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the capital stock of HPPI; and

(vi)

the HP Patents have been irrevocably assigned to HPPI on a royalty free basis; and

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 24

(b)

it will use reasonable commercial efforts to maintain all warehousing, sales, personnel and facilities required to perform its obligations under this Agreement.

16.	Liability, indemnity and insurance

16.1

No exclusion or limitation

HPPI may have certain rights and remedies that cannot be excluded, restricted or modified by agreement. Nothing in this Agreement operates to exclude, restrict or modify the application of any implied condition or warranty, provision, the exercise of any right or remedy, or the imposition of any liability under any law where to do so would contravene that law or cause any term of this Agreement to be void (Non-excludable Obligation).

16.2

Exclusion and disclaimer of implied obligations

Except for the Non-excludable Obligations and the express covenants, representations and warranties set out in this Agreement, MAYNE PHARMA MAKES NO OTHER COVENANTS, REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, THE WARRANTY OF NON INFRINGEMENT, OR ANY OTHER MATTER, ANY SUCH COVENANTS, REPRESENTATIONS AND WARRANTIES BEING EXPRESSLY DISCLAIMED.

16.3

Limitation of liability regarding matters other than Non-Excludable Obligations

Mayne Pharma’s liability to HPPI arising directly or indirectly under or in connection with this Agreement or the performance or non-performance of this Agreement and whether arising under any indemnity, statute, in tort (including for negligence or otherwise (except as provided for below in this clause 16.3)), or on any other basis in law or equity is limited as follows:

***

16.4

Indemnity

HPPI must indemnify and hold harmless and keep indemnified and held harmless Mayne Pharma and each of its Personnel from and against all actions, claims, demands, losses, damages, costs and expenses (including legal expenses as between a solicitor and their own client) howsoever and wheresoever arising, whether during or after the Term, which arise directly or indirectly from or in respect of:

(a)

the research, development or registration activities relating to the Product, directly or indirectly, by HPPI;

(b)

the importation, promotion, marketing, sale or distribution of the Product, directly or indirectly, by HPPI;

(c)

the use or effects of such Product;

(d)

to avoid doubt and without limitation, any actual or alleged infringement of Intellectual Property Rights (but excluding the MP Licensed Rights) arising from any of activities, use or effects referred to in clauses 16.4(a) to 16.4(c),

except to the extent that such action, claim, demand, loss, damage, cost or expense is caused by a breach of an express warranty given under this Agreement by Mayne Pharma or the gross negligence, fraud or wilful misconduct of Mayne Pharma or its Affiliates or Personnel.

16.5

HPPI Insurance

(a)

HPPI must take out, at its own cost, adequate insurance cover for the Term (and in the case of a claims based policy, for *** after), with reputable insurers to the reasonable

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 25

satisfaction of Mayne Pharma, in respect of its liabilities under this Agreement and its activities contemplated by this Agreement, which:

(i)

covers each of HPPI, Mayne Pharma and its Personnel for their respective rights, interests and liabilities (to avoid doubt, in whatever country the liability arises); and

(ii)

notes Mayne Pharma’s interest under the policy.

(b)

Without limiting clause 16.5(a):

(i)

for such period as there is a Mayne Pharma appointee to the board of directors of HPPI, HPPI must take out, at its own cost, adequate director and officer liability insurance cover;

(ii)

clinical trial insurance which provides coverage for at least *** for each occurrence and *** in the aggregate or such other level of cover as agreed in writing by the parties, acting reasonably, and which covers each of HPPI, Mayne Pharma and its Personnel for their respective rights, interests and liability arising directly or indirectly from or in respect of the conduct of any clinical trial for the Product; and

(iii)

from the Actual Launch Date, HPPI must effect product and public liability insurance which provides coverage for at least *** for each occurrence, and which covers each of HPPI, Mayne Pharma and its Personnel for their respective rights, interests and liabilities arising directly or indirectly from or in respect of:

(A)

the research, development or registration activities relating to the Product, directly or indirectly, by HPPI;

(B)

the importation, promotion, marketing, sale or distribution of the Product, directly or indirectly, by HPPI; and

(C)

the use or effects of such Product.

16.6

Mayne Pharma Insurance

Mayne Pharma must effect and maintain product and public liability insurance, with reputable insurers, which provides coverage for at least *** for each occurrence.

16.7

Maintain insurance

Each party must maintain the insurance policies referred to in clause 16.5 or 16.6 (as applicable) throughout the Term and, in the case of a claims-based policy, until *** after the termination or expiry of this Agreement.

16.8

Evidence of insurance

Promptly in response to a request by a party, the other party must provide to the requesting party evidence of the currency of the insurance policies referred to in clause 16.5 or 16.6 (as applicable).

CONFIDENTIALITY AND IPR

17.	Confidentiality

17.1

Definition

Subject to clause 17.3, Confidential Information of a party (in this context, the Disclosing Party) means all information regardless of its form:

(a)

treated by the Disclosing Party as confidential or in which it would be reasonable to expect that the Disclosing Party has an expectation of confidentiality (even if not specifically identified as confidential); and

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 26

(b)

disclosed by the Disclosing Party to the other party or of which the other party becomes aware, whether before or after the Start Date,

and any derived information from which that information can reasonably be ascertained. Without limiting the generality of the foregoing, Confidential Information shall include, information and materials related to Product, processes, formulations, procedures, tests, equipment, data, batch records, reports, know-how, patent positioning, relationships with consultants and employees, business plans and business developments, and information concerning the existence, scope or activities of any research, design, development, manufacturing, marketing or other activities hereunder or otherwise relating to the Disclosing Party or its business.

17.2

Restrictions on disclosure and use

Subject to the exceptions and permitted disclosures set out below, each party (Recipient) agrees:

(a)

to keep the Confidential Information of the Disclosing Party strictly secret and confidential from third parties (including any patent office); and

(b)

to use the Confidential Information only for the purposes of this Agreement or exercise of the rights granted under this Agreement, and not for any other activity (including the purchase or sale or securities of the Disclosing Party in the public markets) without the prior written approval of the other party,

except that each party may share such Confidential Information with any Affiliate, sub licensee or approved contractors to the extent necessary or reasonably desirable for the purposes of this Agreement, provided each party remains responsible for ensuring such Affiliates, sub licensees or contractors comply with restrictions on use and disclosure of information which are at least equivalent to those set out in this Agreement, without any right of further disclosure.

17.3

Exceptions

The restrictions on use and disclosure set out above do not apply to the extent the Recipient can show the information:

(a)

was public knowledge or generally known at the date of its disclosure or which subsequently becomes public knowledge or generally known through no act or failure to act on the part of the Recipient;

(b)

is or was already in the Recipient’s possession and was not acquired directly or indirectly from the Disclosing Party (in each case as shown by the Recipient’s written records);

(c)

is or was acquired by the Recipient in good faith from a third party who was not under an obligation of confidence with respect to that Confidential Information; or

(d)

to the extent it is required by law, rule or regulation to be disclosed (including the U.S. federal securities laws and the rules and regulations of the U.S. Securities and Exchange Commission and the listing rules of the Australian Stock Exchange).

18.	Intellectual Property Rights

18.1

Intellectual Property Rights in the Product as at the Start Date

HPPI acknowledges and agrees that Mayne Pharma owns all Intellectual Property Rights in the Product existing as at the Start Date other than the HP Patents, HPPI Licensed Rights or any Intellectual Property Rights developed exclusively by HPPI or its Affiliates or Personnel prior to the Start Date.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 27

18.2

***

18.3

Reserved

18.4

***

18.5

Development of Intellectual Property Rights and Licence of HPPI Licensed Rights

(a)

From and after the Start Date, all Intellectual Property Rights relating to the Product for its use in the Field that are (i) developed by HPPI, its Affiliates or Personnel; (ii) jointly developed by HPPI and Mayne Pharma and their respective Affiliates and Personnel, or (iii) developed by Mayne Pharma and its Affiliates and Personnel in providing the services referred to in clause 4.4 (collectively, Developed Intellectual Property Rights) shall be the sole and exclusive property of HPPI, and, to the extent created in part by Mayne Pharma, its Affiliates or Personnel, Mayne Pharma hereby irrevocably transfers and assigns to HPPI without additional consideration all such Intellectual Property Rights. Notwithstanding the foregoing, the parties agree with Schedule 7 applies to Developed Intellectual Property Rights.

(b)

All Intellectual Property Rights relating to the Product for its use in the Field that are developed solely by Mayne Pharma, its Affiliates or Personnel from and after the Start Date shall be the sole and exclusive property of Mayne Pharma, but without limiting clause 3.3 of this Agreement.

18.6

Notification of infringement

Each party will immediately notify the other party if it becomes aware of potential or actual:

(a)

infringement of the other party’s Intellectual Property Rights the subject of this Agreement; or

(b)

the infringement of third party rights as a result of the research, development and registration activities relating to the Product, or the manufacture, importation, promotion, marketing, sale or distribution of the Product, as contemplated under this Agreement.

18.7

Right to take action

Each party has the sole right at its own expense to take action in respect of any potential or actual infringement of Intellectual Property Rights it owns, regardless of the grant of any rights, exclusive or otherwise, to the other party under this Agreement. In response to a request by a party taking such action, the other party will provide information and assistance in connection with such potential or alleged infringement to the extent it relates to the Intellectual Property Rights which are the subject of this Agreement, and the requesting party will reimburse to the other party all reasonable costs and expenses incurred as a result.

19.

Branding

19.1

Directions regarding use of the Trade Mark

HPPI may use the Trade Mark in connection with its promotion, marketing, sale and distribution of the Product in the Territory, and must observe all directions notified to it by Mayne Pharma regarding the depiction of its Trade Marks.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 28

19.2

Samples of marketing materials

HPPI must submit to Mayne Pharma samples of all materials (including all advertisements, promotions and other marketing material for the Product) that depict the Trade Mark for approval by Mayne Pharma before use.

19.3

Use of the Trade Mark

HPPI must not, whether during the Term or after the end of this Agreement:

(a)

use the Trade Mark as part of its corporate, business or trading name;

(b)

use any other trade mark or name in conjunction with or in close proximity to the Trade Mark;

(c)

use the Trade Mark in a manner which would jeopardise or invalidate any registration (or prejudice any application for registration) of the Trade Mark or could assist or give rise to an application to terminate, revoke or dilute any such registration; or

(d)

use the Trade Mark in a manner which might prejudice the right or title of Mayne Pharma to the Trade Mark.

19.4

Goodwill

HPPI acknowledges that any goodwill and other such rights in the Trade Marks that may otherwise accrue to HPPI as a result of its use of the Trade Mark, accrue to the benefit of Mayne Pharma.

19.5

No right for HPPI to register the Trade Mark

HPPI must not, whether during the Term or after the end of this Agreement, apply to register anywhere in the Territory or the world any trade mark, or apply to register or use any business name, company name or Internet domain name that comprises or contains the Trade Mark or any words or images that are similar to the Trade Mark without the prior written consent of Mayne Pharma.

TERMINATION

20.	Termination

20.1

Termination for breach by a party

A party may terminate this Agreement with immediate effect by notice in the manner set forth below to the other party if:

(a)

that other party breaches any material provision of this Agreement and fails to remedy the breach within *** after receiving notice requiring it to do so;

(b)

that other party breaches a material provision of this Agreement where that breach is not capable of remedy; or

(c)

any event referred to in clause 20.3 happens to that other party (whether or not notification has been provided under clause 20.3).

20.2

Termination by Mayne Pharma for cause arising under a related agreement

Mayne Pharma may terminate this Agreement with immediate effect by notice to HPPI if:

(a)

any of HPPI, ▇▇▇▇▇▇▇▇▇, LLC, ▇▇▇▇▇ ▇. ▇’▇▇▇▇▇▇▇, ▇▇., M.D. or ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇ breaches a material provision of the Equity Holders Agreement, and:

(i)

fails to remedy the breach within *** after receiving notice requiring it to do so; or

(ii)

that breach is not capable of remedy;

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 29

(b)

HPPI breaches a material provision of the Mayne Pharma Purchase Agreement or the 2015 SPA, and:

(i)

fails to remedy the breach within *** after receiving notice requiring it to do so; or

(ii)

that breach is not capable of remedy.

20.3

Notification of insolvency events

Each party must notify the other party immediately if:

(a)

that party ceases to carry on its business operations;

(b)

that party ceases to be able to pay its debts as they become due;

(c)

any step is taken by a mortgagee or secured party to take possession or dispose of the whole or part of that party’s assets, operations or business;

(d)

that party makes a general assignment for the benefit of creditors;

(e)

that party becomes the subject of the filing or institution of bankruptcy, liquidation or receivership proceedings;

(f)

any step is taken to appoint a receiver, a receiver and manager, a trustee in bankruptcy, a provisional liquidator, a liquidator, an administrator or other like person of the whole or part of that party’s assets, operations or business; or

(g)

an order is made for winding up or dissolution without winding up of that party or an effective resolution is passed for the winding up of that party.

20.4

Change of control and disposal of assets or business by HPPI

(a)

For so long as this Agreement is in effect, HPPI must seek the prior written consent of Mayne Pharma before it disposes of the whole or a substantial part of its assets, operations or business, such consent not to be unreasonably withheld, conditioned or delayed. HPPI must, at its own reasonable expense, provide to Mayne Pharma such information as Mayne Pharma reasonably requires to consider such a request for consent, including an independent third party opinion on valuation that has been approved by the board of HPPI. Without limitation, a breach of this clause is a breach of a material provision of this Agreement not capable of remedy.

(b)

For so long as this Agreement is in effect, HPPI must notify Mayne Pharma before it undergoes any change in its direct or indirect beneficial ownership or control. If, acting reasonably, Mayne Pharma considers that such change will have a material, negative impact on its rights under this Agreement, it may terminate this Agreement by giving *** notice to HPPI.

20.5

Impact of claims of infringement

(a)

If Mayne Pharma becomes subject to, or acting in its discretion, considers it is at risk of becoming subject to, any litigation, arbitration or similar proceeding claiming its activities under this Agreement with respect to the Product infringe the Intellectual Property Rights of any third party (the Third Party IPR), then Mayne Pharma may, at any time while such proceeding or risk remains, with immediate effect by notice to HPPI, elect not to supply Product for commercial sales until:

(i)

Mayne Pharma enters into written agreement under which it obtains an exclusive license to copy and exploit all Intellectual Property Rights in the applicable Third Party IPR; or

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 30

(ii)

all rights arising from the applicable Third Party IPR in the Territory have expired, lapsed or been invalidated by action of Mayne Pharma, HPPI or otherwise.

(b)

During any period that Mayne Pharma has elected not to supply Product for commercial sale under clause 20.5(a):

(i)

Mayne Pharma will supply Product:

(A)

for uses reasonably related to the development and submission of information under a US Federal law which regulates the manufacture, use, or sale of drugs for clinical trials that have already started at the date of the notice until those clinical trials have completed;

(B)

at the Floor Price in accordance with item 5.2(a) of Schedule 5, in which case item 5.1 of Schedule 5 no longer applies;

(ii)

HPPI may allow any Backup Manufacturer to manufacture the Product for commercial sale, in accordance with Schedule 6 except that notwithstanding item 3.1 of Schedule 6, the parties will use their reasonable commercial efforts to Qualify a Backup Manufacturer (both as defined in Schedule 6) within 6 months after consent is provided by Mayne Pharma under item 2 of Schedule 6;

(iii)

recognizing that the exercise by Mayne Pharma of its election under this clause 20.5 to not provide Product for commercial supply would materially impact the timing for any planned commercial launch of the Product in the Field, should Mayne Pharma exercise its rights under this clause 20.5, HPPI and Mayne Pharma shall, with input from the JDC, promptly take action to amend the Development Plan to establish (amongst any other matters the parties may agree) a revised Target Launch Date and resulting date by which the applicable Marketing Authorisation must be obtained to reflect any delay caused by the exercise by Mayne Pharma of its election under this clause 20.5. The parties shall use reasonable commercial efforts to approve such revised Development Plan within 30 days of Mayne Pharma’s election. The parties shall not be bound by or be held in breach of this Agreement for failure to achieve any Target Launch Date or similar deadlines to the extent caused by the exercise by Mayne Pharma of its election under this clause 20.5; and

(iv)

in consideration for Mayne Pharma allowing such manufacture by a Backup Manufacturer, at the end of each Quarter:

(A)

HPPI must notify Mayne Pharma of the quantities of any Product manufactured by the Backup Manufacturer in that Quarter under clause 20.5(b)(ii); and

(B)

HPPI must pay to Mayne Pharma:

Mayne Pharma Sales Share Rate x (the Total Net Sales for that Quarter minus the reasonable cost of goods (per unit) incurred by HPPI to obtain the Product sold in that Quarter from the Backup Manufacturer),

within *** of the date of Mayne Pharma’s notice under clause 20.5(a).

20.6

Accrued rights and remedies

The termination or expiry of this Agreement does not affect any accrued rights or remedies of either party.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 31

20.7

Sell down or repurchase

At the termination or expiry of this Agreement except for termination by Mayne Pharma under clause 20.1 or 20.2:

(a)

Mayne Pharma will fill any Orders provided they are placed *** before the date of the termination or expiry of this Agreement; and

(b)

HPPI may promote, market, sell and distribute any Product for a period of *** from the termination or expiry of this Agreement (in which case, to avoid doubt, the provisions of clause 7, 10 and 11 continue to apply), subject to HPPI meeting its contractual obligations after the termination or expiry of this Agreement.

20.8

Return of Confidential Information

At the termination or expiry of this Agreement for any reason whatsoever:

(a)

each party will, as soon as practicable, return to the other party all of the other party’s Confidential Information (other than Confidential Information comprising part of the HPPI Licensed Rights), whether in permanent or magnetic/computer disk form or any other form provided that each party may:

(i)

provide one copy of that Confidential Information to its legal advisers, to be held by them solely for the purpose of determining the scope of that party’s obligations under this clause; and

(ii)

retain one copy of such of that Confidential Information that is required by the Relevant Regulatory Authority, to be retained by that party.

(b)

HPPI must, within *** after the termination or expiry of this Agreement, deliver to Mayne Pharma, at Mayne Pharma’s option, all advertising, promotional or sales materials relating to the Product which are still in the power, possession or control of HPPI, any of its Affiliates or any Sub Licensee.

GENERAL

21.	Force majeure

21.1

Occurrence of Force Majeure Event

If a Force Majeure Event affecting a party precludes that party (Precluded Party) partially or wholly from complying with its obligations (except its payment obligations) under this Agreement then:

(a)

as soon as reasonably practicable after that Force Majeure Event arises, the Precluded Party must notify the other party in writing of:

(i)

the Force Majeure Event;

(ii)

which obligations the Precluded Party is precluded from performing (Affected Obligations);

(iii)

the extent to which the Force Majeure Event precludes the Precluded Party from performing the Affected Obligations (Precluded Extent); and

(iv)

the expected duration of the delay arising directly out of the Force Majeure Event;

(b)

the Precluded Party’s obligation to perform the Affected Obligations will, to the Precluded Extent, be suspended for the duration of the actual delay arising directly out of the Force Majeure Event; and

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 32

(c)

the other party’s obligations to perform any obligations dependent on the Affected Obligations will be suspended until the Precluded Party resumes performance.

21.2

Termination

If the suspension under clause 21.1(b) continues for more than ***, the other party may terminate this Agreement with immediate effect by giving notice to the Precluded Party.

22.	Notices and other communications

22.1

Service of notices

A notice, demand, consent, approval or communication under this Agreement (Notice) must be:

(a)

in writing, in English and signed by a person duly authorised by the sender; and

(b)

hand delivered or sent by reputable international courier, prepaid post or by facsimile transmission to the recipient’s address for Notices specified in the Details, as varied by any Notice given by the recipient to the sender.

22.2

Effective on receipt

A Notice given in accordance with clause 22.1 takes effect when taken to be received (or at a later time specified in it), and is taken to be received:

(a)

if hand delivered or sent by reputable international courier, on delivery;

(b)

if sent by prepaid post, on the second Business Day after the date of posting (or on the seventh Business Day after the date of posting if posted to or from a place outside Australia);

(c)

if sent by facsimile, when the sender’s facsimile system generates a message confirming successful transmission of the entire Notice unless, within 8 Business Hours after the transmission, the recipient informs the sender that it has not received the entire Notice,

but if the delivery, receipt or transmission is not on a Business Day or is after 5.00pm on a Business Day, the Notice is taken to be received at 9.00am on the next Business Day.

23.	Dispute resolution

In the event of any action, question or disagreement arising from or relating to this Agreement, the parties hereto agree to settle such action, question or disagreement by arbitration before a single arbitrator in Atlanta, Georgia, selected by, and such arbitration to be administered by, the American Arbitration Association (“AAA”) in accordance with its International Arbitration Rules, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Each of the parties hereto agrees and acknowledges that all actions, questions or disagreements between or among them arising from or relating to this Agreement are subject to the alternative dispute resolution procedures of this clause 23. Each of the parties hereto agrees that any aspect of alternative dispute resolution not specifically covered in this Agreement shall be covered, without limitation, by the applicable AAA rules and procedures. Each of the parties hereto further agrees that any determination by the arbitrator regarding any action, question or disagreement arising from or relating to this Agreement shall be final and binding upon the parties hereto and shall not be subject to further appeal.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 33

24.

GST

24.1

Interpretation

(a)

Words or expressions used in this clause 24 which are defined in the A New Tax System (Goods and Services Tax) Act 1999 (Cth) have the same meaning in this clause.

(b)

Clause 25 prevails over this clause 24 to the extent of any inconsistency.

24.2

Consideration is GST exclusive

Any consideration to be paid or provided to the Supplier for a supply made by it under or in connection with this Agreement, unless specifically described in this Agreement as ‘GST inclusive’, does not include an amount on account of GST.

24.3

Gross up of consideration

(a)

Despite any other provision in this Agreement, if the Supplier makes a taxable supply under or in connection with this Agreement (not being a supply the consideration for which is specifically described in this Agreement as ‘GST inclusive’):

(i)

the consideration payable or to be provided for that supply under this Agreement but for the application of this clause (‘GST exclusive consideration’) is increased by, and the Recipient must also pay to the Supplier, an amount equal to the GST payable on the supply (‘GST Amount’); and

(ii)

the GST Amount must be paid to the Supplier by the Recipient without set off, deduction or requirement for demand, at the same time as the GST exclusive consideration is payable or to be provided.

24.4

The sale of the Product is intended to be a GST-free export of goods

(a)

Mayne Pharma and HPPI acknowledge that the supply of the Product under this Agreement is intended to constitute a GST-free supply of exported goods under item 1 of section 38-185(1) of the GST Act.

(b)

HPPI warrants that in relation to each delivery of the Product, it will it satisfy the requirements under:

(i)

Item 1 of section 38-185(1) and section 38-185(3) the GST Act; and

(ii)

The interpretation of those provisions in paragraph (i) as outlined by the Australian Taxation Office in its Public Goods and Services Tax Ruling ‘GSTR 2002/6, Goods and Services Tax: Exports of goods, items 1 to 4A of the table in subsection 38-185(1) of the A New Tax System (Goods and Services Tax) Act 1999’.

(c)

HPPI must provide written evidence to the Supplier that it has satisfied the requirements in clause 24.4(b) within *** of the Supplier issuing an invoice for the relevant Product.

(d)

In the event HPPI fails to satisfy the requirements in clause 24.4(b), clause 24.4(c) or the Australian Taxation Office otherwise determines that the sale of the Product by Mayne Pharma constitutes a taxable supply, HPPI must immediately pay to Mayne Pharma the GST Amount payable in relation to the supply of the Product in accordance with clause 24.3 and any applicable interest, fines and penalties payable by Mayne Pharma as a result of the supply of the Product being treated as a GST-free supply.

24.5

Reimbursements (net down)

If a payment to a party under this Agreement is a reimbursement or indemnification or otherwise calculated by reference to a loss, cost or expense incurred by that party, then the payment will be reduced by the amount of any input tax credit to which that party, or the representative member of the GST group that party is a member of (as the case may be), is entitled in respect of that loss, cost or expense.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 34

24.6

Tax invoices

The Supplier will give the Recipient a tax invoice in respect of a taxable supply made under or in connection with this Agreement.

24.7

Adjustments

If and to the event an adjustment event arises in respect of a supply made under or in connection with this Agreement, then:

(a)

if the Supplier’s corrected GST Amount is less than the previously attributed GST Amount, the Supplier shall refund the difference to the Recipient;

(b)

if the Supplier’s corrected GST Amount is greater than the previously attributed GST Amount, the Recipient shall pay the difference to the Supplier;

(c)

the Supplier must issue an adjustment note to the Recipient within *** of the adjustment event occurring or otherwise as soon as it becomes aware of the adjustment event; and

(d)

any payment under clauses 24.7(a) or 24.7(b) must be paid to the Supplier or Recipient (as the case may be) within *** of the adjustment note being issued by the Supplier.

24.8

Similar goods and services taxes or value added taxes

Clauses 24.2, 24.3 and 24.5 to 24.7 apply with the necessary changes in respect of any similar goods and services taxes or value added taxes levied in jurisdictions outside Australia.

25.

Tax

25.1

Payments free of taxes; obligations to withhold; payments on account of taxes

(a)

Any and all payments to be made to Mayne Pharma under this Agreement must be, to the extent permitted by law, be made free and clear or and without reduction or withholding for any Tax. HPPI acknowledges and agrees that any amount (in cash, securities or property in kind) received by Mayne Pharma or its nominee from HPPI as consideration arising under or related to this Agreement, is deemed to be a payment made to Mayne Pharma under this Agreement.

(b)

Whenever HPPI is required by law to make a deduction or withholding in respect of Tax from any payment to be made to Mayne Pharma under this Agreement, then HPPI will:

(i)

make that deduction or withholding from the payment;

(ii)

promptly pay an amount equal to the amount deducted or withheld as required by law and by the date that Tax is due to be paid to the appropriate governmental or regulatory agency having jurisdiction over HPPI;

(iii)

if requested by Mayne Pharma, within *** of that request, deliver to Mayne Pharma official relevant receipts issued by such Tax authority, if any, received by HPPI or other documentation of HPPI evidencing payment of that amount; and

(c)

pay Mayne Pharma such additional amounts as necessary to ensure Mayne Pharma receives when due a net amount (after deduction or withholding of any Taxes in respect of such additional amounts) equal to the full amount which Mayne Pharma would have received if no deduction or withholding had been made.

25.2

Refunds

Mayne Pharma has no obligation to file or otherwise pursue any refund of Taxes withheld or deducted from funds paid to Mayne Pharma.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 35

26.	Miscellaneous

26.1

Survival of Obligations

Any indemnity or any obligation of confidence under this Agreement is independent and survives termination of this Agreement. Any other term by its nature intended to survive termination of this Agreement survives termination of this Agreement, to avoid doubt, including clause 3.2(b)(i), 7.1, 7.4, 7.5, 12.2(d), 16, 17, 18.1, 18.7, 19.3 to 19.5, 20.6 to 20.8, 23, 24, 25, 26.1, 26.11 and 26.14 and Schedule 7.

26.2

Approvals and consents

Except where this Agreement expressly provides otherwise, a party may, in its discretion, give conditionally or unconditionally or withhold any approval or consent under this Agreement.

26.3

Announcements

Without limiting clause 17, a public announcement by HPPI in connection with this Agreement or any transaction contemplated by it must be approved in writing by Mayne Pharma before it is made, except if required by law or a regulatory body (including any relevant stock exchange), in which case HPPI must, to the extent practicable, first consult with and take into account the reasonable requirements of Mayne Pharma.

26.4

Subcontracting

Each party may appoint contractors to perform its obligations under this Agreement, except that HPPI must obtain the prior written consent of Mayne Pharma before appointing a contractor to perform a material part of the HPPI’s obligations under this Agreement. The appointment of any contractor by a party does not relieve that party of any of its obligations under this Agreement.

26.5

Assignment

(a)

HPPI may assign any of its rights or obligations under this Agreement only with the prior written consent of Mayne Pharma.

(b)

Mayne Pharma may assign any of its rights or obligations under this Agreement to:

(i)

an Affiliate or any entity to whom Mayne Pharma has disposed the whole or a substantial part of its assets, operations or business; or

(ii)

otherwise with the prior written consent of HPPI.

26.6

Costs

Each party must pay its costs and expenses of negotiating, preparing and executing this Agreement.

26.7

Relationship

The relationship of principal and agent does not exist between the parties. Each party is an independent contractor and not an agent of HPPI. Neither party has any authority to act, execute any documents or warrant or represent on behalf of or otherwise bind the other party.

26.8

No modification

This Agreement cannot be modified except in writing and signed by each party.

26.9

Non waiver

A party’s failure to exercise any right conferred on it under this Agreement will not be deemed to be a waiver of that right, unless it is in writing signed by that party. A party’s waiver of any right under this Agreement at any given time is not deemed to be a waiver for any other time.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 36

26.10

Entire agreement

This Agreement, including its schedules, the Equity Holders Agreement, the 2014 Transaction Documents (as defined in the Equity Holders Agreement) and the 2015 Transaction Documents (as defined in the Equity Holders Agreement) and the exhibits, annexes, instruments and the documents contemplated thereby, constitute the entire agreement between the parties in connection with its subject matter and supersedes all previous or contemporaneous agreements, promises or understandings between the parties in connection with its subject matter.

26.11

Further Action

Each party must do, at its own expense, everything reasonably necessary (including executing documents) to give full effect to this Agreement and any transaction contemplated by it.

26.12

Severability

If any term or provision of this Agreement is held to be invalid or unenforceable, it is to be read down so as to be valid or enforceable or, if such reading down is not possible, severed and the remaining terms hereof will not be affected but will be valid and enforced to the fullest extent permitted by law.

26.13

Counterparts

This Agreement may be executed in counterparts, including electronic counterparts. All executed counterparts constitute one document. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

26.14

Governing law

This Agreement is governed by the laws of Delaware, USA, without regard to the conflicts of laws principles thereof.

[Schedules Follow Beginning on Next Page]

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 37

– Agreement details

Start Date

3 September 2013

Initial Term

Starts on the Start Date and continues until the later of:

10 years from the Target Launch Date;

all issued patents of Mayne Pharma or any of its Affiliates referred to in paragraph (a) of the definition of MP Licensed Rights have lapsed or expired.

Territory

United States of America, including all of its commonwealths, territories and possessions.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 38

– Not used

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 39

– Development Plan

To be provided and approved in accordance with clause 4.1(a).

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 40

– Product and Product Specification

Product: SUBA-itraconazole 50mg hard capsules

Hard gelatin capsules, size *** body and cap printed “***” in *** on the cap. Capsules contain white to off-white powder. The outside of the capsule must be free from powder and the two capsule halves must lock firmly together.

Comprehensive product specifications will be agreed between the parties during the conduct of the activities in the Development Plan and will form part of Marketing Authorisation submission to the Relevant Regulatory Authority.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 41

– Economic details

Floor Price, Minimum Order Quantity and Minimum Annual Volumes

Floor Price and Minimum Order Quantity


Product	Floor Price per unit (USD)	Minimum Order Quantity (MOQ) (capsules)	Incremental Order Quantity (after the MOQ) (capsules)
SUBA-itraconazole 50mg hard capsule	***	***	***

Minimum Annual Volumes

***

Forecast Period

***

Delivery terms

EXW (Incoterms 2010), Salisbury, South Australia, Australia.

Minimum shelf life

***

Price

Product Mayne Pharma provides ***

Mayne Pharma will provide Product for the conduct of the activities in the Development Plan and any other activities relating to the research, development or registration activities relating to the Product approved by Mayne Pharma, *** set out in the table below:


Relevant part of the Field for which the Product is used		Maximum capsules free of charge
***		***
***		***
***		***

In response to a request by HPPI following a recommendation by the JDC, Mayne Pharma will review and consider changes to the relevant part of the Field for which the Product is used and/or the maximum number of capsules *** for the purposes of this item 5.1 of this Schedule 5, and may change either or both, acting in its discretion by notice to HPPI.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 42

Product for which Mayne Pharma is ***

HPPI *** Mayne Pharma for:

any Product required for the conduct of the activities in the Development Plan and any other activities relating to the research, development or registration activities relating to the Product:

(i)

above the amount specified in item 5.1 of this Schedule 5; or

(ii)

***,

at the Floor Price, and payable by HPPI within *** of the date of Mayne Pharma’s invoice, to be issued on or after shipment of the Product; and

all other Product, in accordance with this item 5 of this Schedule 5.

Definitions

In this Schedule 5:

Actual ASP means for any ***.

Floor Price means the floor price set out in the table above.

Forecast ASP means the forecasted ***.

***

Price is calculated under item 5.6 of this Schedule 5.

Total Net Sales means ***.

Transfer Price means ***.

Total Units Sold ***.

Forecast ASP

At least *** before the start of each ***, the parties will use reasonable commercial efforts to agree on the forecasted Total Net Sales on a per Product basis and the forecasted Total Units Sold for that ***, which will be used to calculate the Forecast ASP.

Transfer Price

The Transfer Price must be reviewed by the parties, and if necessary, revised at least *** before the start of each ***. The Transfer Price for the Product at the time of invoice is ***.

Price

The Price to be paid by HPPI for the Product in the Territory is:

the Transfer Price, payable by HPPI within *** of the date of Mayne Pharma’s invoice, to be issued on or after shipment of the Product; and

as adjusted by a reconciliation of the Actual ASP in relation to the Forecast ASP *** as follows:

***

Timely accounting for deductions

HPPI must, and must ensure that its Affiliate and any Sub licensee must, promptly process any deduction from Total Net Sales and in any event, process such deductions no later than *** after they are allowed (in the case of discounts, bonuses, commissions and rebates), applied or the Products are rejected or returned.

Books of Account

(a)

HPPI will maintain books of account and records with respect to sales and stocks of the Product supplied by Mayne Pharma under this Agreement in the Territory by HPPI, its Affiliates and Sub Licensee (including stock records) (Books of Account).

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 43

(b)

Mayne Pharma will have the right to appoint, on reasonable notice, a certified accountant who is independent and from a nationally recognised accounting firm (Accountant) to inspect and examine the Books of Account.

(c)

Mayne Pharma will bear the fees of the Accountant unless an error equivalent to *** or more of the Total Net Sales in any calendar year is discovered, in which case the fees will be borne by HPPI.

(d)

HPPI will maintain the Books of Account in accordance with business accounting standards in the Territory and at a standard sufficient to facilitate any Product recall.

(e)

HPPI will have the right to appoint on reasonable notice an Accountant to inspect and examine Mayne Pharma’s manufacturing costs, including Mayne Pharma’s cost of goods as such is relevant to the calculation of the Floor Price.

Reporting requirements

Within *** from the end of each month of each Quarter, HPPI must use reasonable commercial efforts to submit to Mayne Pharma an estimated reconciliation report in reasonable detail.

Currency and exchange rate

Currency

USD

Financial institution for exchange rate

National Bank of Australia Limited

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 44

– Qualification of Backup Manufacturer

Definitions

In this Schedule 6:

***

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 45

– Licence of HPPI Licensed Rights

Licence of HPPI Licensed Rights

Grant of licence

From the Start Date, HPPI grants to Mayne Pharma an exclusive, perpetual, irrevocable, royalty free licence to copy and exploit outside the Territory any Intellectual Property Right (including all Developed Intellectual Property Right subject to clause 18.5 of the Agreement, but excluding rights in respect of trade and service marks and logos) that satisfies all of the following criteria:

relates to, or has potential application in connection with, the Product, including any dossier containing technical or clinical information relating to the Product; and

is owned by HPPI or its Affiliates or Sub Licensees, or licensed by HPPI, its Affiliates or Sub Licensees (without restriction as to license or sub license) at any time during the period starting at the Start Date until the earlier of:

(i)

***; or

(ii)

the termination or expiry of this Agreement,

(HPPI Licensed Rights) including the HP Patents and also including, in respect of Intellectual Property Rights not yet in existence at the Start Date but created before the earlier of the dates referred to in items 1.1(b)(i) and (ii) of this Schedule 7), by way of a grant of a licence of future Intellectual Property Rights, which takes effect from the date of creation of those rights.

HPPI to ensure it remains free to licence the HPPI Licensed Rights

HPPI must:

ensure that, in respect of any Intellectual Property Rights comprising the HPPI Licensed Rights owned by it, its Affiliates or any Sub Licensee; and

use reasonable commercial efforts to ensure that, in respect of any Intellectual Property Rights comprising the HPPI Licensed Rights licensed by it, its Affiliates and any Sub Licensee,

HPPI is free to grant to Mayne Pharma an exclusive, perpetual, irrevocable, royalty free licence to copy and exploit outside the Territory such Intellectual Property Rights. Promptly on becoming aware of any restriction on such right to grant such licence, HPPI must notify Mayne Pharma.

Restriction on assignment or sub licence

The licence under item 1.1 of this Schedule 7 may only be assigned or sub licensed in accordance with this Agreement or otherwise with the prior written consent of HPPI.

Copies of documents, data and other information embodying the HPPI Licensed Rights

Promptly in response to a request by Mayne Pharma at any time during the Term or a reasonable period after the termination or expiry of this Agreement, HPPI must provide to Mayne Pharma a copy of any documents, data and other information embodying the HPPI Licensed Rights since the most recent request by Mayne Pharma under this item 2 of Schedule 7.

Intellectual property protection for HPPI Licensed Rights

HPPI will consult with Mayne Pharma regarding intellectual property protection for such rights outside the Territory.

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 46

In particular, HPPI must give at least *** prior notice before it, or any of its Affiliates:

(i)

discloses any Confidential Information comprised in the HPPI Licensed Rights to any third party unless subject to equivalent restrictions on use and disclosure as those under clause 18, without any right of further disclosure; and

(ii)

without limitation, discloses any Confidential Information comprised in the HPPI Licensed Rights to any patent office, including as part of a patent application.

If HPPI decides not to file, prosecute or maintain patent protection for any invention comprised in the HPPI Licensed Rights in any country outside the Territory, it must promptly give notice to Mayne Pharma (with such notice to be given at least *** before any deadline for decisions relating to such filing, prosecution or maintenance).

Mayne Pharma may, by notice to HPPI, request that HPPI make a decision in respect of the filing, prosecution or maintenance of patent protection for any invention comprised in the HPPI Licensed Rights in any country outside the Territory, in which case HPPI must respond before any deadline referred to in item 3(c) of this Schedule 7 but in any event no later than *** after the request by Mayne Pharma.

If HPPI gives notice to Mayne Pharma under item 3(c) or (d) of this Schedule 7 of its intention not to file, prosecute or maintain patent protection of any invention comprised in the HPPI Licensed Rights in any country outside the Territory, Mayne Pharma may decide to take over such filing, prosecution or maintenance at its cost by giving notice to HPPI before the relevant deadline, in which case:

(i)

HPPI will, or will procure that its Affiliate (as applicable) will, promptly assign to Mayne Pharma or its nominee all rights in respect of the invention (including under any patent application or issued patent); and

(ii)

from the date of such assignment, HPPI acknowledges that:

(A)

such rights no longer form part of the HPPI Licensed Rights;

(B)

Mayne Pharma or its nominee may, in its discretion and at its cost, file, prosecute, maintain, enforce and defend any assigned patent application or issued patent; and

(C)

any information in respect of the invention that is not public knowledge is deemed to be Confidential Information of Mayne Pharma.

Sub licensing and assignment

Sub licensing

Upon notice to HPPI, Mayne Pharma may grant a sub licence of the HPPI Licensed Rights to a third party without the prior written consent of HPPI under a written agreement that includes obligations on that third party that relate to use and disclosure of Intellectual Property Rights of HPPI and Confidential Information of HPPI at least equivalent to those imposed on Mayne Pharma under this Agreement.

Assignment

Despite clause 26.5(b), Mayne Pharma may assign any of its rights or obligations under this Schedule 7 without the prior written consent of HPPI.

[Signature page follows]

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 47

Signed as an AGREEMENT by authorised officers of each party.


Signed for Mayne Pharma Ventures Pty Ltd by an authorised officer in the presence of				/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
				Signature of officer

/s/ ▇▇▇▇ ▇▇▇▇▇▇▇				▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Signature of witness				Name of officer (print)

▇▇▇▇ ▇▇▇▇▇▇▇				CEO and Director
Name of witness (print)				Office held

				May 15, 2015
				Date

Signed for ▇▇▇▇▇▇▇▇▇ Pharmaceuticals, Inc by an authorised officer in the presence of				/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
				Signature of officer

/s/ ▇▇▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇-▇▇▇▇▇				▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Signature of witness				Name of officer (print)

▇▇▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇-▇▇▇▇▇				President and CEO
Name of witness (print)				Office held

				May 15, 2015
				Date

Second Amended and Restated Supply and license agreement – Mayne Pharma and HPPI | page 48

FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665

Document Metadata

Document Metadata

Table of Contents